These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1137 related items for PubMed ID: 11443170

  • 1. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
    Janssen YJ, Hamdy NA, Frölich M, Roelfsema F.
    J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study.
    Appelman-Dijkstra NM, Claessen KM, Hamdy NA, Pereira AM, Biermasz NR.
    Clin Endocrinol (Oxf); 2014 Nov; 81(5):727-35. PubMed ID: 24816144
    [Abstract] [Full Text] [Related]

  • 6. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 7. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.
    Osteoporos Int; 2006 Sep; 17(5):716-23. PubMed ID: 16463007
    [Abstract] [Full Text] [Related]

  • 8. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus.
    Pivonello R, Faggiano A, Di Somma C, Klain M, Filippella M, Salvatore M, Lombardi G, Colao A.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2349-52. PubMed ID: 10404801
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
    Longobardi S, Di Rella F, Pivonello R, Di Somma C, Klain M, Maurelli L, Scarpa R, Colao A, Merola B, Lombardi G.
    J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
    Greenspan SL, Resnick NM, Parker RA.
    J Clin Endocrinol Metab; 2005 May; 90(5):2762-7. PubMed ID: 15713726
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 16. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up.
    Finkenstedt G, Gasser RW, Höfle G, Watfah C, Fridrich L.
    Eur J Endocrinol; 1997 Mar; 136(3):282-9. PubMed ID: 9100553
    [Abstract] [Full Text] [Related]

  • 17. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S, Kainberger F, Frisch H, Geyer G, Hörl WH, Mayer G, Luger A.
    J Nephrol; 2004 Mar; 17(1):87-94. PubMed ID: 15151263
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 19. Impact of the growth hormone replacement on bone status in growth hormone deficient adults.
    Kužma M, Kužmová Z, Zelinková Z, Killinger Z, Vaňuga P, Lazurová I, Tomková S, Payer J.
    Growth Horm IGF Res; 2014 Feb; 24(1):22-8. PubMed ID: 24382377
    [Abstract] [Full Text] [Related]

  • 20. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study.
    Drake WM, Rodríguez-Arnao J, Weaver JU, James IT, Coyte D, Spector TD, Besser GM, Monson JP.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):525-32. PubMed ID: 11318789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.